U.S. Stem Cell, Inc. (USRM)
OTCMKTS
· Delayed Price · Currency is USD
0.00
0.00 (0.00%)
At close: Aug 14, 2024
U.S. Stem Cell Statistics
Total Valuation
U.S. Stem Cell has a market cap or net worth of 662. The enterprise value is 10.08 million.
| Market Cap | 662 |
| Enterprise Value | 10.08M |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
U.S. Stem Cell has 661.51 million shares outstanding.
| Shares Outstanding | 661.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +4.18% |
| Owned by Insiders (%) | 6.01% |
| Owned by Institutions (%) | n/a |
| Float | 581.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.01 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.53 |
| EV / Sales | 122.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1,806.66% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 7,459 |
| Profits Per Employee | -259,813 |
| Employee Count | 11 |
| Asset Turnover | 1.38 |
| Inventory Turnover | 34.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 44.02 |
| Average Volume (20 Days) | 264,085 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, U.S. Stem Cell had revenue of 82,049 and -2.86 million in losses. Loss per share was -0.00.
| Revenue | 82,049 |
| Gross Profit | 58,282 |
| Operating Income | -1.72M |
| Pretax Income | -2.86M |
| Net Income | -2.86M |
| EBITDA | n/a |
| EBIT | -1.72M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 5,133 in cash and 10.08 million in debt, giving a net cash position of -10.08 million or -0.02 per share.
| Cash & Cash Equivalents | 5,133 |
| Total Debt | 10.08M |
| Net Cash | -10.08M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -14.75M |
| Book Value Per Share | -0.02 |
| Working Capital | -14.01M |
Cash Flow
| Operating Cash Flow | -304,852 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 71.03% |
| Operating Margin | -2,096.90% |
| Pretax Margin | -3,483.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
U.S. Stem Cell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.38% |
| Shareholder Yield | -28.38% |
| Earnings Yield | -483,100.00% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 4, 2015. It was a reverse split with a ratio of 0.001.
| Last Split Date | Nov 4, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.001 |
Scores
U.S. Stem Cell has an Altman Z-Score of -3261.68. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3261.68 |
| Piotroski F-Score | n/a |